Immuron reveals anti-COVID potential, raises $28 million

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.